OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial () with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology...
MidWestOne Financial Group, Inc. Reports Financial Results for the Third Quarter of 2025 IOWA CITY, Iowa, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) ("we," "our," or the "Company") today reported results for the third quarter of 2025. Third Quarter 2025 Summary1 Net income of $17.0 million, or $0.82 per diluted common share. Adjusted earnings of $18.1 million, or $0.872 per common share. Noninterest income was $10.3 million, which included a negative MSR valuation adjustment of $611 thousand.Noninterest expense was $37.6 million, which included a $...
Nicolet Bankshares, Inc. Announces Merger with MidWestOne Financial Group, Inc. Combination creates premier community banking franchise in the Upper Midwest GREEN BAY, Wis. and IOWA CITY, Iowa, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nicolet Bankshares, Inc. (NYSE: NIC) (“Nicolet”) and MidWestOne Financial Group, Inc., (NASDAQ: MOFG) (“MidWestOne”) jointly announced today the execution of a definitive merger agreement pursuant to which Nicolet will acquire MidWestOne and its wholly-owned banking subsidiary, MidWestOne Bank. Based on the financial results as of September 30, 2025, the combine...
OPKO Health to Report Third Quarter 2025 Financial Results on October 29 MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages parti...
MidWestOne Financial Group, Inc. Announces Third Quarter 2025 Earnings Conference Call IOWA CITY, Iowa, Oct. 10, 2025 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“MidWestOne” or the “Company”), parent company of MidWestOne Bank, today announced that its third quarter 2025 financial results will be released after market closes on Thursday, October 23, 2025. The Company will host a conference call to discuss its financial results at 11:00 a.m. Central Time on Friday, October 24, 2025. Investors and analysts interested in participating in the call may pre-register u...
A director at Cincinnati Financial Corp sold 3,500 shares at 153.544USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.